Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure (Q44241712)

1 December 2017

Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure (English)

1 reference

1 December 2017

1 reference

Henry D Jampel

1

1 reference

1 December 2017

Jason Bacharach

2

1 reference

1 December 2017

Wang-Pui Sheu

3

1 reference

1 December 2017

Lisa G Wohl

4

1 reference

1 December 2017

Alfred M Solish

5

1 reference

1 December 2017

William Christie

6

1 reference

1 December 2017

Latanoprost/Unoprostone Study Group

7

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

American Journal of Ophthalmology

1 December 2017

1 reference

1 December 2017

134

1 reference

1 December 2017

6

1 reference

1 December 2017

863-871

1 reference

Clinical evaluation of nerve fiber layer atrophy as an indicator of glaucomatous optic nerve damage

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Number of people with glaucoma worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Medical Management of Glaucoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Scanning electron microscopic studies of the trabecular meshwork and the canal of Schlemm--an attempt to localize the main resistance to outflow of aqueous humor in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Why is intraocular pressure elevated in chronic simple glaucoma? Anatomical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Acetazolamide and Outflow Facility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Prostaglandin analogues in the treatment of glaucoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

A comparison of intraocular pressure-lowering effect of prostaglandin F2 -alpha analogues, latanoprost, and unoprostone isopropyl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901820-2

10.1016/S0002-9394(02)01820-2

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference